undamentalytics Newsletter
Sign in

Adma Biologics, Inc. revenue

Adma Biologics, Inc.'s revenue was $510m in fiscal 2025, up 19.6% on the year before. Since fiscal 2011 ($761,042) it has grown at a compound 59.2% a year. Over the last twelve months it was $512m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue11367112317294281154258426510512
Growth on the year before—+46.9%+174.4%+92.8%+21.3%+48.5%+113.5%−25.4%+72.8%+43.9%+91.7%+90.4%+67.6%+65.2%+19.6%—
Gross profit101234−6−25−10−1913589220293331

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
ADMA Bio Manufacturing $493M 96.7% ▲ 18.6%
Plasma Collection Centers $17M 3.3% ▲ 62.1%
Geography
Region Revenue Share YoY
United States $504M 98.8% ▲ 22.9%
Outside the US $6.1M 1.2% ▼ 62.6%

From Adma Biologics, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Adma Biologics, Inc. $512m 8.0% 35.0%
Hutchmed (china) Ltd $549m -13.0% —
Krystal Biotech, Inc. $470m 26.0% 280.1%
Arcutis Biotherapeutics, Inc. $464m 76.1% 241.4%
Cormedix Inc. $462m 280.5% 1135.4%
Ardelyx, Inc. $451m 16.8% 75.9%

Compare with peers

Head to head: ADMA vs HCMADMA vs KRYSADMA vs ARQT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Adma Biologics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Adma Biologics, Inc.